Teriparatide versus risedronic acid in men with glucocorticosteroid-induced osteoporosis

Trial Profile

Teriparatide versus risedronic acid in men with glucocorticosteroid-induced osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2013

At a glance

  • Drugs Risedronic acid; Teriparatide
  • Indications Male osteoporosis
  • Focus Therapeutic Use
  • Acronyms EuroGIOPS
  • Sponsors Lilly Research Centre
  • Most Recent Events

    • 11 Oct 2011 New trial record
    • 20 Sep 2011 Results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top